The litigation focuses on the period between July 30, 2025, and February 24, 2026, during which Beta Bionics marketed the iLet device as a low-engagement, highly automated solution. While executives publicly dismissed FDA inspection findings as routine administrative matters, the complaint alleges they actively suppressed data concerning serious hypoglycemic incidents. The situation shifted on February 24, 2026, when the FDA issued a scathing warning letter to CEO Sean Saint.
In section Releases
Beta Bionics Faces Class Action Lawsuit Over iLet Safety Disclosures
Investors are targeting Beta Bionics in a federal securities class action, alleging the medical device company concealed thousands of safety complaints regarding its iLet insulin delivery system. The lawsuit claims management misled shareholders by downplaying FDA scrutiny while failing to report life-threatening adverse events to federal regulators.
Regulators documented significant failures in the company’s quality management, specifically noting that Beta Bionics neglected to investigate malfunctions linked to adverse health outcomes. The FDA further stated the firm failed to report potential causes of death or serious injury within the mandatory 30-day window. Hagens Berman, the firm leading the investigation, contends that the company prioritized revenue over patient safety, resulting in substantial financial losses for shareholders as the true nature of the regulatory violations surfaced. Investors seeking to participate in the class action must meet a November 3, 2026, deadline.
Comments (0)
No comments yet. Be the first!